<?xml version="1.0" encoding="UTF-8"?>
<ref id="cam41388-bib-0021">
 <label>21</label>
 <mixed-citation publication-type="journal" id="cam41388-cit-0021">
  <string-name>
   <surname>Blackwell</surname>, 
   <given-names>K.</given-names>
  </string-name>, 
  <string-name>
   <given-names>R.</given-names>
   <surname>Donskih</surname>
  </string-name>, 
  <string-name>
   <given-names>C. M.</given-names>
   <surname>Jones</surname>
  </string-name>, 
  <string-name>
   <given-names>A.</given-names>
   <surname>Nixon</surname>
  </string-name>, 
  <string-name>
   <given-names>M. J.</given-names>
   <surname>Vidal</surname>
  </string-name>, 
  <string-name>
   <given-names>R.</given-names>
   <surname>Nakov</surname>
  </string-name>, et al. 
  <year>2016</year>
  <article-title>A comparison of proposed biosimilar LA‐EP2006 and reference pegfilgrastim for the prevention of neutropenia in patients with early‐stage breast cancer receiving myelosuppressive adjuvant or neoadjuvant chemotherapy: pegfilgrastim randomized oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT‐2), a Phase III, Randomized</article-title>. 
  <source>Double‐Blind Trial. Oncologist.</source>
  <volume>21</volume>:
  <fpage>789</fpage>–
  <lpage>794</lpage>.
  <pub-id pub-id-type="pmid">27091420</pub-id>
 </mixed-citation>
</ref>
